Skip to main content
ConductScienceScienceDex

Dooley, Kelly E.

From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.

FY2023 NIH rank #13,311
Unclaimed recordClaim profile
  • R01 Holder

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2014 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2023

Linked Award Amount
$803.3K
Full award amounts, FY2023
Award Records
3
Records listing this PI
Award-Linked Rank
#13,311
By linked amount among FY2023 PIs
Earliest Year Loaded
2014
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Dooley, Kelly E.. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2023 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2023 award records by amount

NIH award records listing Dooley, Kelly E. as a PI. Multi-PI records show the full award amount for context.

  • 3R01AI152142-04S1R01Contact PI
    Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
    Centre/Aids Programme/Res/South Africa
    $369.9K
    award amount
  • 5R01AI152142-04R01Contact PI
    Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
    Centre/Aids Programme/Res/South Africa
    $303.5K
    award amount
  • 3R01AI152142-03S1R01Contact PI
    Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
    Centre/Aids Programme/Res/South Africa
    $129.8K
    award amount

Award organization

Organizations that administered FY2023 awards listing Dooley, Kelly E. as a PI.

FY2023 award administered by Centre/Aids Programme/Res/South Africa ().

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2014
    First NIH Award
    Centre/Aids Programme/Res/South Africa
  2. 2014
    $500K Cumulative Funding
  3. 2015
    $1M Cumulative Funding
  4. 2016
    $2M Cumulative Funding
  5. 2016
    Entered Top 50% Nationally
    Ranked #7562
  6. 2017
    R01 Grant Holder
  7. 2021
    $5M Cumulative Funding

Explore further

Find collaborators for Dooley, Kelly E.

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →